Back to Search
Start Over
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
- Source :
- BMC Cancer; 7/23/2021, Vol. 21 Issue 1, p1-9, 9p
- Publication Year :
- 2021
-
Abstract
- <bold>Background: </bold>Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC). Due to the lack of evidence to directly compare them, we conducted this network meta-analysis to indirectly compare the effectiveness and toxicity of modified FOLFIRINOX and GEM-NAB.<bold>Methods: </bold>The eligible retrospective studies on treatments related to modified FOLFIRINOX and GEM-NAB up to 4 April 2020 were searched and assessed. We used the frequentist model to analyze the survival and toxicity data between different treatments. Pooled analysis for overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and events of toxicity were analyzed in this study.<bold>Results: </bold>Twenty-two studies were involved in this network meta-analysis. The comparisons on OS and PFS showed that modified FOLFIRINOX and GEM-NAB had similar treatment efficacy (OS: 1.13; 95% CI: 0.78-1.63; PFS: HR: 1.19; 95% CI: 0.85-1.67). GEM-NAB was more effective than modified FOLFIRINOX based on the result of ORR (RR: 1.43; 95% CI: 1.04-1.96). Moreover, our analysis showed a similar toxicity profile between modified FOLFIRINOX and GEM-NAB.<bold>Conclusions: </bold>The current evidence showed that modified FOLFIRINOX and GEM-NAB were similar in survival and toxicity. Many factors should be considered for in the formulation of optimal treatment, and our meta-analysis could provide some guidance to treatment selection in the first-line setting for advanced PC. [ABSTRACT FROM AUTHOR]
- Subjects :
- PANCREATIC cancer
OVERALL survival
PROGRESSION-free survival
SURVIVAL analysis (Biometry)
TREATMENT effectiveness
CANCER chemotherapy
GEMCITABINE
THERAPEUTIC use of antineoplastic agents
PANCREATIC tumors
PUBLICATION bias
ALBUMINS
FOLINIC acid
RESEARCH
META-analysis
RESEARCH methodology
PROGNOSIS
ANTINEOPLASTIC agents
DEOXYCYTIDINE
MEDICAL cooperation
EVALUATION research
FLUOROURACIL
TUMOR classification
COMPARATIVE studies
RESEARCH funding
PACLITAXEL
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 21
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- BMC Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 151541176
- Full Text :
- https://doi.org/10.1186/s12885-021-08605-x